JP2020530496A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530496A5 JP2020530496A5 JP2020530436A JP2020530436A JP2020530496A5 JP 2020530496 A5 JP2020530496 A5 JP 2020530496A5 JP 2020530436 A JP2020530436 A JP 2020530436A JP 2020530436 A JP2020530436 A JP 2020530436A JP 2020530496 A5 JP2020530496 A5 JP 2020530496A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- chlorophenyl
- amino
- pharmaceutically acceptable
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CC1=CNC2N=*N=C(*)C12 Chemical compound CC1=CNC2N=*N=C(*)C12 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543141P | 2017-08-09 | 2017-08-09 | |
| US62/543,141 | 2017-08-09 | ||
| US201862630581P | 2018-02-14 | 2018-02-14 | |
| US62/630,581 | 2018-02-14 | ||
| US201862664442P | 2018-04-30 | 2018-04-30 | |
| US62/664,442 | 2018-04-30 | ||
| PCT/US2018/046057 WO2019032859A1 (en) | 2017-08-09 | 2018-08-09 | SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530496A JP2020530496A (ja) | 2020-10-22 |
| JP2020530496A5 true JP2020530496A5 (OSRAM) | 2021-09-16 |
Family
ID=63405398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530436A Ceased JP2020530496A (ja) | 2017-08-09 | 2018-08-09 | タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10570140B2 (OSRAM) |
| EP (2) | EP3939986A1 (OSRAM) |
| JP (1) | JP2020530496A (OSRAM) |
| KR (1) | KR20200036922A (OSRAM) |
| CN (1) | CN111527099B (OSRAM) |
| AU (1) | AU2018313910B2 (OSRAM) |
| BR (1) | BR112020002736A2 (OSRAM) |
| CA (1) | CA3072439A1 (OSRAM) |
| DK (1) | DK3665179T3 (OSRAM) |
| ES (1) | ES2885180T3 (OSRAM) |
| IL (1) | IL272519B (OSRAM) |
| MA (1) | MA49840A (OSRAM) |
| MX (1) | MX2020001598A (OSRAM) |
| PL (1) | PL3665179T3 (OSRAM) |
| PT (1) | PT3665179T (OSRAM) |
| UA (1) | UA126481C2 (OSRAM) |
| WO (1) | WO2019032859A1 (OSRAM) |
| ZA (1) | ZA202000773B (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3939986A1 (en) * | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2020243178A1 (en) * | 2019-05-30 | 2020-12-03 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as prmt5 inhibitors |
| JP7328241B2 (ja) | 2018-03-14 | 2023-08-16 | プレリュード セラピューティクス，インコーポレイティド | タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤 |
| US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| US12173026B2 (en) * | 2018-08-07 | 2024-12-24 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| EP3833669A4 (en) * | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
| KR20210129051A (ko) * | 2019-02-13 | 2021-10-27 | 프렐루드 테라퓨틱스, 인코포레이티드 | 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제 |
| CA3134779A1 (en) * | 2019-03-25 | 2020-10-01 | California Institute Of Technology | Prmt5 inhibitors and uses thereof |
| US12440506B2 (en) | 2019-04-05 | 2025-10-14 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| JP2022527556A (ja) * | 2019-04-05 | 2022-06-02 | プレリュード・セラピューティクス・インコーポレイテッド | プロテインアルギニンメチルトランスフェラーゼ５の選択的阻害剤 |
| EP4031555A1 (en) | 2019-09-18 | 2022-07-27 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2021079196A2 (en) * | 2019-10-21 | 2021-04-29 | Accent Therapeutics, Inc | Mettl3 modulators |
| JP7624985B2 (ja) | 2019-10-22 | 2025-01-31 | ルピン・リミテッド | Ｐｒｍｔ５阻害剤の組合せ医薬 |
| WO2021086879A1 (en) | 2019-10-28 | 2021-05-06 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2022026892A1 (en) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
| IL301509A (en) | 2020-09-21 | 2023-05-01 | Prelude Therapeutics Inc | Cdk inhibitors and their use as pharmaceuticals |
| US20220251088A1 (en) * | 2020-12-10 | 2022-08-11 | Prelude Therapeutics, Incorporated | Processes for Making PRMT5 Inhibitors |
| AU2021400942A1 (en) * | 2020-12-16 | 2023-07-06 | Amgen Inc. | PRMT5 inhibitors |
| CA3205652A1 (en) | 2020-12-18 | 2022-06-23 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| TW202321246A (zh) * | 2021-07-20 | 2023-06-01 | 大陸商上海齊魯製藥研究中心有限公司 | Prmt5抑制劑 |
| US20230181589A1 (en) * | 2021-12-03 | 2023-06-15 | The Trustees Of Indiana University | Prmt5 inhibitors for ocular therapy |
| US11939340B2 (en) | 2022-01-21 | 2024-03-26 | Prelude Therapeutics Incorporated | CDK inhibitors and their use as pharmaceuticals |
| US20230257394A1 (en) | 2022-02-03 | 2023-08-17 | Prelude Therapeutics, Incorporated | CDK Inhibitors And Their Use As Pharmaceuticals |
| US20240018136A1 (en) | 2022-03-09 | 2024-01-18 | Prelude Therapeutics, Incorporated | CDK Inhibitors And Their Use As Pharmaceuticals |
| AU2022448546A1 (en) | 2022-03-23 | 2024-10-17 | Prelude Therapeutics, Incorporated | Polymorphic compounds and uses thereof |
| CN116655638B (zh) * | 2022-05-12 | 2024-01-26 | 上海齐鲁制药研究中心有限公司 | 氘代prmt5抑制剂 |
| WO2024077216A1 (en) | 2022-10-06 | 2024-04-11 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| WO2024216249A1 (en) | 2023-04-14 | 2024-10-17 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| CN116554194A (zh) * | 2023-05-23 | 2023-08-08 | 江苏八巨药业有限公司 | 一种卡培他滨中间体的合成方法 |
| WO2025064402A1 (en) * | 2023-09-22 | 2025-03-27 | St. Jude Children's Research Hospital, Inc. | Method for treating sickle cell disease by targeting senescent cells |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| DE102010060118A1 (de) * | 2010-10-22 | 2012-04-26 | Röhm Gmbh | Stirnseitenmitnehmer |
| US9145438B2 (en) | 2010-12-03 | 2015-09-29 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| PE20180318A1 (es) * | 2011-01-10 | 2018-02-09 | Infinity Pharmaceuticals Inc | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| US9604930B2 (en) * | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| WO2014153214A1 (en) * | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
| EP2975938A4 (en) * | 2013-03-15 | 2017-02-15 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
| US20170210751A1 (en) * | 2014-06-25 | 2017-07-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3160477A4 (en) * | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2016066582A1 (en) | 2014-10-28 | 2016-05-06 | Bci Pharma | Nucleoside kinase inhibitors |
| KR101719881B1 (ko) * | 2014-12-22 | 2017-03-24 | 삼성전기주식회사 | 렌즈 모듈 |
| CN107278205A (zh) * | 2015-02-24 | 2017-10-20 | 辉瑞大药厂 | 用作抗癌药的取代的核苷衍生物 |
| AR104326A1 (es) * | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| TWI730980B (zh) | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| AU2017230658B2 (en) | 2016-03-10 | 2021-03-04 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| WO2017218802A1 (en) | 2016-06-15 | 2017-12-21 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| WO2018075601A1 (en) | 2016-10-18 | 2018-04-26 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018085833A2 (en) | 2016-11-07 | 2018-05-11 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyl transferase 5 (prmt5) |
| WO2018085818A1 (en) | 2016-11-07 | 2018-05-11 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018152501A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018152548A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018160824A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018160855A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| EP3939986A1 (en) | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US11524962B2 (en) | 2017-10-26 | 2022-12-13 | Prelude Therapeutics, Incorporated | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5) |
| EP3833669A4 (en) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
-
2018
- 2018-08-09 EP EP21178139.8A patent/EP3939986A1/en not_active Withdrawn
- 2018-08-09 BR BR112020002736-7A patent/BR112020002736A2/pt not_active Application Discontinuation
- 2018-08-09 CA CA3072439A patent/CA3072439A1/en active Pending
- 2018-08-09 MX MX2020001598A patent/MX2020001598A/es unknown
- 2018-08-09 ES ES18760136T patent/ES2885180T3/es active Active
- 2018-08-09 UA UAA202000927A patent/UA126481C2/uk unknown
- 2018-08-09 WO PCT/US2018/046057 patent/WO2019032859A1/en not_active Ceased
- 2018-08-09 JP JP2020530436A patent/JP2020530496A/ja not_active Ceased
- 2018-08-09 KR KR1020207006384A patent/KR20200036922A/ko not_active Ceased
- 2018-08-09 DK DK18760136.4T patent/DK3665179T3/da active
- 2018-08-09 AU AU2018313910A patent/AU2018313910B2/en not_active Ceased
- 2018-08-09 CN CN201880065979.7A patent/CN111527099B/zh not_active Expired - Fee Related
- 2018-08-09 PT PT187601364T patent/PT3665179T/pt unknown
- 2018-08-09 EP EP18760136.4A patent/EP3665179B1/en active Active
- 2018-08-09 US US16/059,909 patent/US10570140B2/en active Active
- 2018-08-09 MA MA049840A patent/MA49840A/fr unknown
- 2018-08-09 PL PL18760136T patent/PL3665179T3/pl unknown
-
2020
- 2020-01-16 US US16/744,771 patent/US11078205B2/en not_active Expired - Fee Related
- 2020-02-05 ZA ZA2020/00773A patent/ZA202000773B/en unknown
- 2020-02-06 IL IL272519A patent/IL272519B/en unknown
- 2020-08-05 US US16/985,643 patent/US11208416B2/en active Active
-
2021
- 2021-11-18 US US17/529,781 patent/US20220153747A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530496A5 (OSRAM) | ||
| ES2612378T3 (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas como inhibidores de cinasa MKNK | |
| AU2020371295B2 (en) | Pharmaceutical combination of PRMT5 inhibitors | |
| CN102015739B (zh) | 化合物以及用于治疗的方法 | |
| IL282916B1 (en) | Fused cyclic chemical compounds and their uses in the treatment of ras-mediated diorders | |
| US20140357636A1 (en) | Treatment of Skeletal-Related Disorders | |
| ES2910071T3 (es) | Compuestos de aminopirazina diol como inhibidores de PI3K-Y | |
| ES2639402T3 (es) | 2,3-dihidroimidazo[1,2-c]quinolinas sustituidas con arilaminoalcohol | |
| EA012869B1 (ru) | Замещённые пиримидины, композиции на их основе и применение замещенных пиримидинов в качестве ингибиторов протеинкиназ | |
| SA111320735B1 (ar) | إيميدازوبيريدازينات مستبدلة | |
| JP2016516821A5 (OSRAM) | ||
| US20230053946A1 (en) | Combinations | |
| JP2015515961A5 (OSRAM) | ||
| JP2015505816A5 (OSRAM) | ||
| US20230087941A1 (en) | Combinations | |
| TW202015693A (zh) | 治療pi3k 相關病症之給藥方案 | |
| KR20220119442A (ko) | 조합 | |
| ES2863250T3 (es) | Tratamiento de trastornos neurológicos | |
| US20230068370A1 (en) | Combinations | |
| US20230054767A1 (en) | Combinations | |
| US20230042653A1 (en) | Combinations | |
| US20220241310A1 (en) | Thiarabine- and thiarabine prodrug-based treatments | |
| WO2021127042A1 (en) | Combinations | |
| HK40042521B (zh) | 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法 | |
| TH152248A (th) | 2-อัลไคนิล-และ 2-อัลคีนิล-ไพราโซโล-[4,3-e]-1,2,4-ไตรอะโซโล-[1,5-c]-ไพริมิดีน ที่เป็นแอนทาโกนิสท์ของตัวรับอะดีโนซีนA2a |